ChAdOx1.HIVconsv62

BIOLOGICAL4 trials

Sponsors

University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID), Henry M. Jackson Foundation for the Advancement of Military Medicine, University of Oxford

Conditions

ARTAcute HIV InfectionHIVHIV InfectionsHIV VaccineHIV-1-infectionPLWH

Phase 1

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

CompletedNCT05604209

University of North Carolina, Chapel HillHIV-1-infection, HIV Vaccine

Start: 2022-10-13End: 2025-01-10Updated: 2025-08-24

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

RecruitingNCT06071767

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1-infection

Start: 2024-04-01End: 2029-08-01Target: 36Updated: 2026-02-09

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

RecruitingNCT06484335

Henry M. Jackson Foundation for the Advancement of Military MedicineAcute HIV Infection, ART, HIV Infections +1

Start: 2025-03-27End: 2027-08-01Target: 48Updated: 2025-09-16

Phase 2

Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV

RecruitingNCT07054931

University of OxfordHIV

Start: 2025-09-05End: 2028-06-30Target: 48Updated: 2026-01-21

Related Papers

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Nature Communications2025-03-0416 citations